- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Weinberg on the Efficacy of BXCL701 Plus Pembrolizumab in Pretreated, Metastatic PDAC
July 3rd 2025, 9:46am
ESMO Gastrointestinal Cancers Congress
Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.
Invikafusp Alfa Generates Antitumor Activity in PD-(L)1–Resistant and –Naive, Antigen-Rich GI Tumors
July 2nd 2025, 7:34pm
ESMO Gastrointestinal Cancers Congress
Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.
Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC
July 2nd 2025, 7:22pm
ESMO Gastrointestinal Cancers Congress
Irpagratinib combined with atezolizumab was effective and safe in both treatment-naive and ICI-exposed advanced HCC with FGF19 overexpression.
Certepetide Plus Chemotherapy Shows ORR, PFS Benefits Over Placebo in Metastatic PDAC
July 2nd 2025, 7:20pm
ESMO Gastrointestinal Cancers Congress
Certepetide plus gemcitabine and nab-paclitaxel was safe and effective in patients with untreated metastatic pancreatic ductal adenocarcinoma.
Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs
July 2nd 2025, 6:22pm
ESMO Gastrointestinal Cancers Congress
Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.
Low KIM-1 Levels Are Associated With Improved Clinical Outcomes in Advanced RCC
July 2nd 2025, 2:00pm
A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.
Clinical "Gray Areas" Persist Amid Evolving Multiple Myeloma Treatment Strategies
July 2nd 2025, 12:02pm
Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma
Ajai Chari, MD, expands on areas of uncertainty in multiple myeloma after his presentation at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials
July 1st 2025, 8:24pm
Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.
Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer
June 30th 2025, 9:12pm
Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.
Approaches to Risk Stratification, Timing of Treatment Initiation Pose Challenges in Smoldering Myeloma
June 30th 2025, 8:00pm
Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma
Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer
June 25th 2025, 9:43pm
ESMO Gynecological Cancers Congress
Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.
Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC
June 24th 2025, 3:28pm
Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.
Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer
June 24th 2025, 1:00pm
Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.
Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases
June 23rd 2025, 3:28pm
Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.
First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer
June 22nd 2025, 12:00pm
ESMO Gynecological Cancers Congress
Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.
Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer
June 21st 2025, 7:39pm
ESMO Gynecological Cancers Congress
Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
June 20th 2025, 5:41pm
ESMO Gynecological Cancers Congress
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.
PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer
June 19th 2025, 9:49pm
Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.
BGB-16673 Displays a High ORR and Tolerability in Waldenström Macroglobulinemia
June 19th 2025, 8:57pm
European Hematology Association Congress
BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.
Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC
June 19th 2025, 8:42pm
Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.